ANI Pharmaceuticals reports Q1 non-GAAP EPS $2.05, consensus $1.30

Reports Q1 revenue $237.46M, consensus $207.63M. “We delivered a strong first quarter, generating $237.5M in revenue and $63.0M in adjusted non-GAAP EBITDA, with solid performance across all business units,” said Nikhil Lalwani, President and CEO of ANI. “We are seeing continued momentum in demand for Cortrophin Gel and have made meaningful progress advancing our organizational expansion focused on capturing the opportunity in acute gouty arthritis flares, with the majority of our commercial team now onboarded. We remain confident in Cortrophin Gel’s long-term growth potential and are well positioned to drive adoption in underpenetrated specialty indications, while the strength of our Generics business continues to support investment in our Rare Disease portfolio.”